This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

InDex Pharmaceuticals Holding Beheer

Beheer criteriumcontroles 2/4

De CEO InDex Pharmaceuticals Holding is Jenny Sundqvist, benoemd in Jan2023, heeft een ambtstermijn van 1.42 jaar. De totale jaarlijkse vergoeding van { bedraagt SEK 3.54M, bestaande uit 64% salaris en 36% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.023% van de aandelen van het bedrijf, ter waarde SEK 65.60K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.6 jaar en 8.4 jaar.

Belangrijke informatie

Jenny Sundqvist

Algemeen directeur

SEK 3.5m

Totale compensatie

Percentage CEO-salaris	64.0%
Dienstverband CEO	1.4yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	4.6yrs
Gemiddelde ambtstermijn bestuur	8.4yrs

Recente managementupdates

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Jul 11

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Jan 21

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Aug 31

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

Mar 29

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

Feb 04

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Dec 21

Analyse CEO-vergoeding

Hoe is Jenny Sundqvist's beloning veranderd ten opzichte van InDex Pharmaceuticals Holding's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2024	n/a	n/a	-SEK 56m
Dec 31 2023	SEK 4m	SEK 2m	-SEK 95m

Compensatie versus markt: De totale vergoeding ($USD 338.03K ) Jenny } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Swedish markt ($USD 236.52K ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Jenny te vergelijken met de prestaties van het bedrijf.

CEO

Jenny Sundqvist (53 yo)

1.4yrs

Tenure

SEK 3,543,000

Compensatie

Ms. Jenny Sundqvist serves as Chief Executive Officer of InDex Pharmaceuticals Holding AB (publ) since January 01, 2023. She served as Chief Commercial Officer of Isofol Medical AB (publ) from January 1, 2...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jenny Sundqvist	Chief Executive Officer	1.4yrs	SEK 3.54m	0.023% SEK 65.6k
Johan Gileus	Deputy CEO & Chief Financial Officer	7.1yrs	SEK 2.80m	0.073% SEK 209.8k
Charlotte Admyre	Chief Scientific Officer	2.1yrs	geen gegevens	0.0017% SEK 4.9k
Margareth Jorvid	Head of Regulatory Affairs	11.4yrs	geen gegevens	geen gegevens

4.6yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INDEX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lennart Hansson	Independent Director	13.4yrs	SEK 235.00k	0.081% SEK 232.4k
Uli Hacksell	Independent Director	8.4yrs	SEK 235.00k	0.077% SEK 219.5k
Karl Tobieson	Director	less than a year	geen gegevens	geen gegevens
Brian Gordon Feagan	Member of Advisory Board - North America	no data	geen gegevens	geen gegevens
Geert D'Haens	Member of Advisory Board - Europe	no data	geen gegevens	geen gegevens
Wenche Rolfsen	Independent Chairman	13.4yrs	SEK 500.00k	0.14% SEK 406.6k
Walter Reinisch	Member of Advisory Board - Europe	no data	geen gegevens	geen gegevens
Laurent Peyrin-Biroulet	Chairman of Advisory Board - Europe	2yrs	geen gegevens	geen gegevens
Raja Atreya	Member of Advisory Board - Europe	no data	geen gegevens	geen gegevens
Jonas Halfvarson	Member of Advisory Board - Europe	no data	geen gegevens	geen gegevens
Franco Scaldaferri	Member of Advisory Board - Europe	no data	geen gegevens	geen gegevens
Christina Ha	Member of Advisory Board - North America	no data	geen gegevens	geen gegevens

8.4yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INDEX wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.4 jaar).

This company is no longer active

InDex Pharmaceuticals Holding Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

InDex Pharmaceuticals Holding AB (publ) Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024

InDex Pharmaceuticals Holding AB (publ) Announces Composition of the Nomination Committee

Deputy CEO & Chief Financial Officer recently bought kr66k worth of stock

InDex Pharmaceuticals Holding AB (publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

InDex Pharmaceuticals Holding AB (publ) Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024

InDex Pharmaceuticals Holding AB (publ) Discontinues the Development of Cobitolimod

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

InDex Pharmaceuticals Holding AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

Third quarter 2023 earnings released: kr0.07 loss per share (vs kr0.006 loss in 3Q 2022)

New major risk - Share price stability

InDex Pharmaceuticals Holding AB (publ) Discontinues Cobitolimod Phase III Program

InDex Pharmaceuticals Holding AB (publ) Announces Composition of the Nomination Committee

InDex Pharmaceuticals Holding AB (Publ) Receives New Patent for Cobitolimod in South Korea

InDex Pharmaceuticals Holding AB (publ) Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude

InDex Pharmaceuticals Holding AB (publ) Announces Positive Results from the Pharmacokinetic (PK) Study

InDex Pharmaceuticals Holding AB (publ) Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Deputy CEO & Chief Financial Officer recently bought kr66k worth of stock

Price target decreased by 31% to kr1.90

InDex Pharmaceuticals Holding AB (publ) Updates the Timeline of the Phase III Study CONCLUDE with cobitolimod

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Final Results on Apr 12, 2023

InDex Pharmaceuticals Holding AB (publ) to Report Q1, 2023 Results on May 24, 2023

Third quarter 2022 earnings released: kr0.006 loss per share (vs kr0.05 loss in 3Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

InDex Pharmaceuticals Holding AB (publ) Appoints Jenny Sundqvist as New CEO, Effective January 1, 2023

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: kr0.04 loss per share (vs kr0.08 loss in 2Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Successful Interactions with the Pmda for the Clinical Development of Cobitolimod in Japan

InDex Pharmaceuticals Holding AB (publ) Announces Board Appointments

First quarter 2022 earnings released: kr0.04 loss per share (vs kr0.02 loss in 1Q 2021)

InDex Pharmaceuticals Strengthens the Organization with Eva Arlander as Chief Development Officer and Announces Changes in the Composition of the Management Team

Full year 2021 earnings released: kr0.21 loss per share (vs kr0.24 loss in FY 2020)

InDex Pharmaceuticals Holding AB (publ) Announces CEO Changes

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Full year 2021 earnings: EPS misses analyst expectations

InDex Pharmaceuticals Holding AB (publ) Announces Resignation of Pernilla Sandwall as Chief Operating Officer

InDex Pharmaceuticals Enrols First Patient in the Pk Study with Cobitolimod

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

InDex Pharmaceuticals Holding AB (publ) Enrolls First Patient in Phase III Study CONCLUDE with Cobitolimod in Ulcerative Colitis

Second quarter 2021 earnings released

InDex Pharmaceuticals Receives FDA Clearance to start the Phase III Study CONCLUDE with Cobitolimod

InDex Pharmaceuticals Holding AB (publ) to Conduct Clinical Pharmacokinetic Study (PK Study) with Cobitolimod in Sweden

InDex Pharmaceuticals Receives First Regulatory Approval to Start the Phase III study CONCLUDE with Cobitolimod

Independent Director Stig Pedersen has left the company

Independent Director Yilmaz Mahshid has left the company

InDex Pharmaceuticals Holding AB (publ) Announces Patient Recruitment for Phase III Study CONCLUDE is Planned to Initiate after Summer

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

InDex Pharmaceuticals Holding AB (Publ) Announces Changes in the Nomination Committee for the 2021 Annual General Meeting

Revenue in line with expectations

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 23, 2021

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

New 90-day low: kr3.88

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

New 90-day low: kr3.91

InDex Pharmaceuticals Holding AB (publ) Announces Nomination Committee

New 90-day low: kr5.26

Third quarter 2020 earnings released: kr0.09 loss per share

New 90-day low: kr7.00

The Lancet Gastroenterology and Hepatology Publishes Index Pharmaceuticals Holding AB (publ) Results of the Phase IIb Study with Cobitolimod

Chief Executive Officer recently bought kr152k worth of stock

Earnings released

New 90-day high - kr9.38